Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 474 All time
- Disclosed funding
- $19.6B 401 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AT Alloy TherapeuticsCompany profile Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners. Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners. | $40M | Series ESeries C+ | Biotech | United States | Investors | |
| ST Develops non-invasive HIFU therapy system for cancer treatment | $18M | Series A | Biotech, Healthtech | United States | Investors | |
| ST Develops novel therapies for inner ear disorders | $27M | Series B | Biotech | United States | Investors | |
| CF Develops sustainable oils and fats through fermentation | £4.5M | Undisclosed | Biotech, Foodtech | United Kingdom | Investors | |
| H Develops virtual AI lab for pharmaceutical research and development | $10M | Seed | Biotech | Luxembourg | Investors | |
| A AdcendoCompany profile Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma. Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma. | $75M | Series CSeries C+ | Biotech | Denmark | Investors | |
| L LightcastCompany profile Develops functional single-cell analysis tools and platforms for life science research Develops functional single-cell analysis tools and platforms for life science research | $27M | Undisclosed | Biotech | United Kingdom | Investors | |
| QB Develops therapeutics for central nervous system disorders | Undisclosed | StrategicUndisclosed | Biotech | United States | Investors | |
| VT Develops extrahepatic RNA-targeting therapeutics | $54M | Series A | Biotech | China | Investors | |
| OT Oricell TherapeuticsCompany profile Develops next-generation cell therapies for oncology and immunology Develops next-generation cell therapies for oncology and immunology | $110M | Pre-IPOUndisclosed | Biotech | China | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →